Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).

Krista L LanctôtClara ChenEthan MahAlex KissAbby LiDave ShadeRoberta W SchererDanielle VieiraHamadou CoulibalyPaul B RosenbergAlan J LernerPrasad R PadalaOlga Brawman-MintzerChristopher H van DyckAnton P PorsteinssonSuzanne CraftAllan LeveyWilliam J BurkeJacobo MintzerNathan Herrmann

Published in: International psychogeriatrics (2023)

Results from this study indicated that there was no evidence for a difference in resource utilization costs between methylphenidate and placebo treatment. However, utility improved significantly over the 6-month follow-up period. These results can aid in decision-making to improve quality of life in patients with Alzheimer's disease while considering the burden on the healthcare system.

Keyphrases

attention deficit hyperactivity disorder
decision making
phase iii
mild cognitive impairment
cognitive decline
clinical trial
study protocol
randomized controlled trial
cognitive impairment
molecular docking
double blind
phase ii